Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 26, 2019	Jun. 30, 2018
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	VTVT
Entity Registrant Name	vTv Therapeutics Inc.
Entity Central Index Key	0001641489
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 10,955,991
Class A Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		22,792,716
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		23,094,221

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,683,000	$ 11,758,000
Restricted cash and cash equivalents		162,000
Accounts receivable, net	0	8,000,000
Prepaid expenses and other current assets	666,000	442,000
Current deposits	1,124,000
Total current assets	3,473,000	20,362,000
Restricted cash and cash equivalents, long-term	2,500,000	2,500,000
Property and equipment, net	70,000	283,000
Long-term investments	2,480,000	2,480,000
Long-term deposits	36,000	2,292,000
Total assets	8,559,000	27,917,000
Current liabilities:
Accounts payable and accrued expenses	7,702,000	13,901,000
Current portion of deferred revenue	1,752,000	8,757,000
Current portion of notes payable	9,383,000	4,271,000
Total current liabilities	18,837,000	26,929,000
Notes payable, net of current portion	6,330,000	15,316,000
Deferred revenue, net of current portion	1,067,000	4,497,000
Warrant liability, related party	2,436,000	492,000
Other liabilities	260,000	290,000
Total liabilities	28,930,000	47,524,000
Commitments and contingencies
Redeemable noncontrolling interest	62,482,000	131,440,000
Stockholders’ deficit:
Additional paid-in capital	150,595,000	127,682,000
Accumulated deficit	(233,883,000)	(279,058,000)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	(82,853,000)	(151,047,000)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit	8,559,000	27,917,000
Class A Common Stock [Member]
Stockholders’ deficit:
Common stock value	203,000	97,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	203,000	97,000
Class B Common Stock [Member]
Stockholders’ deficit:
Common stock value	232,000	232,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	$ 232,000	$ 232,000

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jul. 29, 2015
Class A Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01			$ 0.01
Common stock, shares authorized	100,000,000	100,000,000			100,000,000
Common stock, shares outstanding	20,347,065	9,693,254	9,693,254	9,156,686
Class B Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01			$ 0.01
Common stock, shares authorized	100,000,000	100,000,000			100,000,000
Common stock, shares outstanding	23,094,221	23,119,246	23,119,246	23,655,814

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 12,434,000	$ 291,000	$ 634,000
Operating expenses:
Research and development	23,035,000	39,640,000	44,953,000
Research and development – related party			795,000
General and administrative	9,223,000	11,333,000	9,906,000
Total operating expenses	32,258,000	50,973,000	55,654,000
Operating loss	(19,824,000)	(50,682,000)	(55,020,000)
Other income (loss)	46,000		(22,000)
Other expense – related party	(638,000)	(190,000)
Interest income	61,000	117,000	87,000
Interest expense	(3,290,000)	(3,092,000)	(398,000)
Loss before income taxes and noncontrolling interest	(23,645,000)	(53,847,000)	(55,353,000)
Income tax provision	200,000	800,000	0
Net loss before noncontrolling interest	(23,845,000)	(54,647,000)	(55,353,000)
Less: net loss attributable to noncontrolling interest	(15,934,000)	(38,503,000)	(39,001,000)
Net loss attributable to vTv Therapeutics Inc.	(7,911,000)	(16,144,000)	(16,352,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (8,650,000)	$ (16,144,000)	$ (16,352,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.69)	$ (1.67)	$ (1.71)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	12,449,236	9,693,254	9,545,527

Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - USD ($) $ in Thousands	Total	Redeemable Noncontrolling Interest [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2015	$ (77,970)		$ 92	$ 237	$ 117,686	$ (195,985)
Beginning balance, redeemable convertible preferred units at Dec. 31, 2015		$ 161,531
Beginning balance, shares at Dec. 31, 2015			9,156,686	23,655,814
Net loss	(16,352)	(39,001)				(16,352)
Share-based compensation	2,641				2,641
Issuance of warrants to purchase Class A Common Stock	721				721
Exchange of Class B Common Stock for Class A Common Stock	3,164	(3,164)	$ 5	$ (5)	3,164
Exchange of Class B Common Stock for Class A Common Stock, shares			536,568	(536,568)
Change in redemption value of noncontrolling interest	(3,149)	3,149				(3,149)
Ending balance at Dec. 31, 2016	(90,945)		$ 97	$ 232	124,212	(215,486)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2016		122,515
Ending balance, shares at Dec. 31, 2016			9,693,254	23,119,246
Net loss	(16,144)	(38,503)				(16,144)
Share-based compensation	3,645				3,645
Issuance of warrants to purchase Class A Common Stock	167				167
Issuance of Letter Agreement and warrants to purchase Class A Common Stock - related party	(342)				(342)
Change in redemption value of noncontrolling interest	(47,428)	47,428				(47,428)
Ending balance at Dec. 31, 2017	(151,047)		$ 97	$ 232	127,682	(279,058)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2017	131,440	131,440
Ending balance, shares at Dec. 31, 2017			9,693,254	23,119,246
Net loss	(7,911)	(15,934)				(7,911)
Cumulative effect of accounting change	213					213
Share-based compensation	2,676				2,676
Exchange of Class B Common Stock for Class A Common Stock	151	(151)			151
Exchange of Class B Common Stock for Class A Common Stock, shares			25,025	(25,025)
Issuance of Class A Common Stockto a related party under the Letter Agreements	21,500		$ 106		21,394
Issuance of Class A Common Stock to a related party under the Letter Agreements, shares			10,617,119
Issuance of Letter Agreement and warrants to purchase Class A Common Stock - related party	(1,308)				(1,308)
Vesting of restricted stock units, shares			11,667
Change in redemption value of noncontrolling interest	52,873	(52,873)				52,873
Ending balance at Dec. 31, 2018	(82,853)		$ 203	$ 232	$ 150,595	$ (233,883)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2018	$ 62,482	$ 62,482
Ending balance, shares at Dec. 31, 2018			20,347,065	23,094,221

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss before noncontrolling interest	$ (23,845)	$ (54,647)	$ (55,353)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Gain on disposal of property and equipment, net	(12)	(11)	(2)
Depreciation expense	218	197	265
Share-based compensation expense	2,676	3,645	2,641
Change in fair value of warrants, related party	638	190
Amortization of debt discount	1,014	1,029	154
Changes in assets and liabilities:
Accounts receivable	8,000	(8,000)	69
Prepaid expenses and other assets	(1,135)	170	502
Employee loans receivable – related party			49
Long-term deposits	2,256	(358)	(261)
Accounts payable and accrued expenses	(6,199)	2,448	4,786
Accounts payable and accrued expenses – related party			(880)
Deferred revenue	(10,435)	10,753	(198)
Other liabilities	(32)	24	19
Net cash used in operating activities	(26,856)	(44,560)	(48,209)
Cash flows from investing activities:
Proceeds from sale of assets	12	32	4
Purchases of property and equipment	(5)	(57)	(87)
Net cash provided by (used in) investing activities	7	(25)	(83)
Cash flows from financing activities:
Issuance of Class A Common Stock to a related party under the Letter Agreements	21,500
Proceeds from debt issuance	500	7,500	12,500
Debt issuance costs			(673)
Repayment of notes payable	(5,388)		(33)
Net cash provided by financing activities	16,612	7,500	11,794
Net decrease in cash, cash equivalents and restricted cash and cash equivalents	(10,237)	(37,085)	(36,498)
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of year	14,420	51,505	88,003
Total cash, cash equivalents and restricted cash and cash equivalents, end of year	4,183	14,420	51,505
Supplemental cash flow information:
Cash paid for interest	2,276	2,064	242
Cash paid for income taxes	1,000
Non-cash activities:
Receipt of investment as partial consideration for license agreement		2,480
Change in redemption value of noncontrolling interest	52,873	(47,428)	(3,149)
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock	151		3,164
Issuance of Letter Agreements and warrants to purchase vTv Therapeutics Inc. Class A Common Stock to a related party	1,308	302
Issuance of warrants to purchase vTv Therapeutics Inc. Class A Common Stock			923
Redeemable Noncontrolling Interest [Member]
Non-cash activities:
Change in redemption value of noncontrolling interest	$ (52,873)	$ 47,428	$ 3,149

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

Note 1: Description of Business and Basis of Presentation

Description of Business

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”), was incorporated in the state of Delaware in April 2015. The Company was formed to discover and develop orally administered small molecule drug candidates to fill significant unmet medical needs.

Principles of Consolidation

vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Consolidated Financial Statements. Various holders own non-voting interests in vTv LLC, representing a 53.2% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 46.8% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (“vTv Units”) of vTv LLC or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B Common Stock”)) for shares of Class A Common Stock (or cash) pursuant to the Exchange Agreement among the Company, vTv LLC and the holders of vTv Units party thereto (the “Exchange Agreement”). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the IPO in 2015, its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016 and its entrance into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”), in December 2017, July 2018 and December 2018 (the “Letter Agreements”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC outside of its obligations pertaining to the Loan Agreement as a co-borrower. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. The creditors of vTv LLC do not have any recourse to the general credit of vTv Therapeutics Inc. except as allowed under the provisions of the Loan Agreement. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.

Going Concern and Liquidity

To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of the Company’s drug candidates will require additional financing. From its inception through December 31, 2018, the Company has funded its operations primarily through a combination of debt and equity financings, research collaboration agreements, upfront and milestone payments for license agreements and private placements of preferred equity. As of December 31, 2018, the Company had an accumulated deficit of $233.9 million and has generated net losses in each year of its existence. The Company’s currently available sources of liquidity include the Company’s cash and cash equivalents balance as of December 31, 2018 of $1.7 million and the $8.5 million of remaining funds available under the Letter Agreements, which management believes will allow the Company to continue its operations and activities for a period of less than twelve months from the issuance of these Consolidated Financial Statements.

Based on the Company’s current operating plan, management believes that the current cash and cash equivalents and remaining funds under the Letter Agreements will allow the Company to meet its liquidity requirements into March 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. While both studies within the Phase 3 STEADFAST study failed to meet their co-primary endpoints, we have initiated start-up activities for an adaptive Phase 2/3 trial to evaluate azeliragon as a potential treatment of mild-AD in patients with type 2 diabetes. The Company is evaluating several financing strategies to fund this clinical trial, including direct equity investments and future public offerings of our common stock. The timing and availability of such financing are not yet known.

The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of its Class B Common Stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Reclassifications

To facilitate comparison of information across periods, certain reclassifications have been made to prior period amounts to conform to the current period’s presentation.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.

Accounts receivable as of December 31, 2017, consisted entirely of the upfront payment due in connection with the License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”) which was fully received in January 2018. There were no accounts receivable at December 31, 2018 and 2016.

Three customers represented 100% of the revenue earned during the year ended December 31, 2018. Four customers represented 100% of the revenue earned during the year ended December 31, 2017. Two customers represented 100% of the revenue earned during the year ended December 31, 2016.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents relate to cash that has been received through a research, development and commercialization agreement with JDRF International (“JDRF”) (the “JDRF Agreement”) but has not yet been utilized to fund the development activities required under the JDRF Agreement. Restricted cash and cash equivalents, long-term relates to the minimum balance that the Company must maintain in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement pursuant to the Loan Agreement, as amended.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets as of December 31, 2018 and 2017 that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows (in thousands):

	2018		2017
Cash and cash equivalents	$	1,683	$	11,758
Restricted cash and cash equivalents		—		162
Restricted cash and cash equivalents, long-term		2,500		2,500
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	4,183	$	14,420

Collaboration Revenue and Accounts Receivable

The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements.

Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.

Property and Equipment and other Long-lived Assets

The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements are depreciated over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance and recorded an impairment charge of $0.1 million during the year ended December 31, 2018. No such charges were recognized during the years ended December 31, 2017 and 2016. There were no assets held for sale at December 31, 2018 or 2017.

Investments

In connection with the Reneo License Agreement, the Company received common stock and certain participation rights representing a minority equity interest in Reneo that is classified as a long-term investment in the Company’s Consolidated Balance Sheet as of December 31, 2017. Upon acquisition, on December 21, 2017, this investment was recognized at its fair value of $2.5 million. This investment is accounted for under the cost method because the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over Reneo.

On January 1, 2018, the Company adopted ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. This guidance requires equity investments to be measured at fair value with changes in fair value recognized in net income. Since it does not have a readily determinable market value, the Company has elected to measure its investment in Reneo at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

No adjustments have been made to the value of the Company’s investment in Reneo since its acquisition either due to impairment or based on observable price changes.

Revenue Recognition

On January 1, 2018, the Company adopted ASC Topic 606, “Revenue From Contracts With Customers” (“ASC Topic 606”), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning after January 1, 2018 are presented under ASC Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC Topic 605.

The Company recorded a net reduction to its opening accumulated deficit of $0.2 million as of January 1, 2018 due to the cumulative impact of adopting ASC Topic 606. This impact related to the recognition of an asset for the incremental costs of obtaining contracts.

The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.

The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernable pattern over which the services will be provided.

Fair Value of Financial Instruments

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Consolidated Statements of Operations as the Company receives the related goods or services.

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

From its formation on August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, the Company’s predecessor entities were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level.

vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.

The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.

The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented.

Noncontrolling Interest

The Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B Common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. See discussion and additional detail of the redeemable noncontrolling interest at Note 11.

Segment and Geographic Information

Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.

Share-Based Compensation

Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on the historical volatility of its own stock as well as a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. The fair value of restricted stock units (“RSU”) grants are based on the market value of the Class A Common Stock on the date of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates.

Comprehensive Income

The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements.

Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue From Contracts With Customers”, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The Company adopted this guidance as of January 1, 2018 using the modified retrospective transition method. See Note 2 – “Revenue Recognition” for further details.

In January 2016, the FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”, which amends ASC 825-10, “Financial Instruments – Overall”. This ASU amends various aspects of the recognition, measurement, presentation and disclosure of financial instruments. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this guidance in the first quarter of fiscal 2018. The Company has elected to use the measurement alternative, defined as cost, less impairments, adjusted by observable price changes. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements. See Note 2 – “Investments” for further details.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU 2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company adopted this guidance in the first quarter of fiscal 2018. The adoption of this guidance did not have a material impact on the Company's Consolidated Financial Statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which increases transparency and comparability among companies accounting for lease transactions. The most significant change of this update will require the recognition by a lessee of lease assets and liabilities on its balance sheet for operating lease arrangements with lease terms greater than 12 months. This update will require a modified retrospective application which includes a number of optional practical expedients related to the identification and classification of leases commenced before the effective date. This ASU is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will result in the recognition of additional assets and liabilities of approximately $0.3 million related to the Company’s operating leases within its Consolidated Balance Sheets.

Collaboration Agreements

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreements

Note 3: Collaboration Agreements

Reneo License Agreement

On December 21, 2017, the Company entered into the Reneo License Agreement, under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans. Under the terms of the Reneo License Agreement, Reneo paid the Company an upfront cash payment of $3.0 million. The Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In addition, Reneo is obligated to pay the Company royalty payments at mid-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company has also received common stock and certain participation rights representing a minority equity interest in Reneo.

Pursuant to the terms of the Reneo License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Reneo License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2018, as it is not considered probable that such payments will be received. The unrecognized amount of the transaction price allocated to this performance obligation as of December 31, 2018 was $1.7 million.

The Company determined that there was no discernable pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the transfer service period. The remainder of this performance obligation will be recognized over approximately 5.5 months. For the years ended December 31, 2018 and 2017, $3.7 million and $0.1 million of revenue has been recognized related to this combined performance obligation, respectively. No such amounts were recognized for the year ended December 31, 2016.

Huadong License Agreement

On December 21, 2017, the Company entered into a License Agreement with Huadong (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. Under the terms of the Huadong License Agreement, Huadong paid the Company an initial license fee of $8.0 million and is obligated to pay potential development and regulatory milestone payments totaling up to $25.0 million, with an additional potential regulatory milestone of $20.0 million if Huadong receives regulatory approval for a central nervous system indication. In addition, the Company is eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products.

Under the Huadong License Agreement, the Company is also responsible for conducting a Phase 2 multi-region clinical trial (the “Phase 2 MRCT”) including sites in both the United States and Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. The Phase 2 MRCT will be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a Phase 3 clinical trial in China. The Company will be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT.

In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Huadong License Agreement. The significant performance obligations were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date (iii) the obligation to sponsor and conduct the Phase 2 MRCT, (iv) the Company’s obligation to participate on a joint development committee, and (v) other obligations considered to be de minimis in nature.

The transaction price has been allocated to these performance obligations based on their relative standalone selling prices, which were estimated using an expected cost plus margin approach. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2018, as it is not considered probable that such payments will be received.

The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernable pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company determined that the straight-line method would be used to recognize revenue for this performance obligation over the transfer service period. In November 2018, the Company received notification from Huadong that the Company had satisfied its obligations related to the technology transfer services. As such, this performance obligation is considered complete as of December 31, 2018 and all of revenue associated with it has been recognized. For the years ended December 31, 2018 and 2017, $6.8 million and $0.1 million of revenue has been recognized related to this combined performance obligation, respectively. No such revenue was recognized for the year ended December 31, 2016.

The Company also determined that the obligation to sponsor and conduct a portion of the Phase 2 MRCT should be treated as a separate performance obligation. A portion of the total consideration received under the Huadong License Agreement was allocated to this performance obligation based on its estimated standalone selling price. Since the Company has not yet begun the Phase 2 MRCT trial, the entire amount remains deferred as of December 31, 2018 and revenue will be recognized using the proportional performance model over the period during which the Company conducts the Phase 2 MRCT trial. The unrecognized amount of the transaction price allocated to this performance obligation as of December 31, 2018 was $1.0 million. No revenue for this performance obligation has been recognized as of December 31, 2018.

The Company also determined that the obligation to participate in the joint development committee (the “JDC”) to oversee the development of products and the Phase 2 MRCT in accordance with the development plan should be treated as a separate performance obligation. A portion of the total consideration received under the Huadong License Agreement was allocated to this performance obligation based on its estimated standalone selling price. A portion of this amount remains deferred as of December 31, 2018 and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. An immaterial amount of revenue for this performance obligation has been recognized during the year ended December 31, 2018. The unrecognized amount of the transaction price allocated to this performance obligation as of December 31, 2018 was $0.1 million. No revenue was recognized for this performance obligation for the years ended December 31, 2017 and 2016.

Newsoara License Agreement

On May 31, 2018, the Company entered into a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”), under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China and other Pacific Rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. Under the terms of the Newsoara License Agreement, Newsoara paid the Company an upfront cash payment of $2.0 million. The Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $63.0 million. In addition, Newsoara is obligated to pay the Company royalty payments at high-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country.

Pursuant to the terms of the Newsoara License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2018, as it is not considered probable that such payments will be received.

The Company determined that there was no discernable pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the transfer service period. The total $2.0 million of the transaction price allocated to this performance obligation was recognized during the year ended December 31, 2018. No revenue was recognized for this performance obligation for the years ended December 31, 2017 and 2016.

JDRF Agreement

In August 2017, the Company entered into the JDRF Agreement to support the funding of the simplici-T1 Study, an adaptive Phase 1b/2 study to explore the effects of TTP399 in type 1 diabetics. We initiated this study in the fourth quarter of 2017. According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.0 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes.

Payments that the Company receives from JDRF under this agreement are recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of December 31, 2018, the Company had received funding under this agreement of $0.8 million, and research and development costs were offset by $0.8 million.

Calithera License Agreement

In March 2015, the Company entered into the Calithera License Agreement under which Calithera obtained an exclusive, worldwide sublicenseable license to develop and commercialize certain of our hexokinase II inhibitors for any therapeutic, prophylactic, preventative or diagnostic use. Under the terms of the Calithera License Agreement, Calithera paid the Company an initial license fee of $0.6 million and a total of $0.3 million for employees of the Company to assist with the development of additional hexokinase inhibitors. This agreement was terminated, at the option of Calithera, effective December 21, 2017.

Contract Liabilities

Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):

	December 31, 2018		December 31, 2017
Current portion of deferred revenue	$	1,752	$	8,757
Deferred revenue, net of current portion		1,067		4,497
Total contract liabilities	$	2,819	$	13,254
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$	10,434	$	21

There were no changes in the estimated transaction prices for the related contracts during the year ended December 31, 2018.

Share-Based Compensation

12 Months Ended

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

Note 4: Share-Based Compensation

In conjunction with the Company’s initial public offering (“IPO”), the board of directors of vTv Therapeutics Inc. (the “Board of Directors”) and sole stockholder adopted a long-term equity incentive plan, the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (the “Plan”). The Plan provides for the grant of stock options, restricted stock, restricted stock units and other awards based on our Class A Common Stock to management, other key employees, consultants and non-employee directors on terms and subject to conditions as established by our Compensation Committee. In settlement of its obligations under this plan, the Company will issue new shares of Class A Common Stock. The maximum number of shares of the Company’s Class A Common Stock that has been approved and may be subject to awards under the Plan is 3.25 million, subject to adjustment in accordance with terms of the Plan.

The Company has issued non-qualified stock option awards and restricted stock units to certain employees, consultants and non-employee directors of the Company. These awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. For the years ended December 31, 2018, 2017 and 2016, the Company recognized $2.7 million, $3.6 million and $2.6 million of compensation expense related to share-based awards, respectively. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2018, the Company had total unrecognized stock-based compensation expense of approximately $1.3 million, which is expected to be recognized on a straight-line basis over a weighted average period of 1.3 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2018, 2017 and 2016 was $2.28, $4.15 and $4.05 per option, respectively.

The aggregate intrinsic value of the in-the-money awards outstanding as of December 31, 2018 was $0.1 million, of which an immaterial amount related to vested stock options and $0.1 million related to unvested stock options.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2018, 2017 and 2016:

	For the Year Ended December 31,
	2018	2017	2016
Expected volatility	71.15% - 99.23%	68.72% - 85.93%	81.57% - 87.23%
Expected life of option, in years	5.7 - 6.0	5.8 - 6.0	5.0 - 6.0
Risk-free interest rate	2.69% - 2.84%	1.87% - 2.24%	1.22% - 1.45%
Expected dividend yield	0.00%	0.00%	0.00%

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2018 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2017		1,960,732		$	8.50
Granted		102,750			3.25
Forfeited		(295,979	)		6.27
Awards outstanding at December 31, 2018		1,767,503		$	8.57
Options exercisable at December 31, 2018		1,180,735		$	10.12
Weighted average remaining contractual term	7.1 Years
Options vested and expected to vest at December 31, 2018		1,737,666		$	8.62
Weighted average remaining contractual term	7.5 Years

The following table summarizes the activity related to the awards of RSUs for the year ended December 31, 2018:

	Number of Shares			Weighted- Average Grant Date Fair Value
Awards outstanding at December 31, 2017		35,000		$	5.81
Vested		(11,667	)		5.81
Awards outstanding at December 31, 2018		23,333		$	5.81
RSUs expected to vest at December 31, 2018		23,012		$	5.81

As of December 31, 2018, the Company had total unrecognized stock-based compensation expense for its outstanding RSU awards of approximately $0.1 million, which is expected to be recognized over a weighted-average period of 1.2 years.

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2018		2017		2016
Research and development	$	994	$	1,485	$	975
General and administrative		1,682		2,160		1,666
Total share-based compensation expense	$	2,676	$	3,645	$	2,641

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2018

Prepaid Expense And Other Assets Current [Abstract]

Disclosure - Prepaid Expenses and Other Current Assets

Note 5: Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	December 31,
	2018		2017
Prepaid insurance	$	571	$	251
Prepaid - other		95		191
Total	$	666	$	442

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Property and Equipment

Note 6: Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2018			2017
Laboratory equipment	$	5,690		$	6,275
Leasehold improvements		1,548			1,679
Computers and hardware		329			323
Software		691			691
Furniture and office equipment		243			431
Total property and equipment		8,501			9,399
Less: accumulated depreciation and amortization		(8,431	)		(9,116	)
Property and equipment, net	$	70		$	283

Depreciation expense, including amounts pertaining to assets held under capital leases, was $0.2 million, $0.2 million and $0.3 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 7: Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2018		2017
Accounts payable	$	2,899	$	2,269
Accrued development costs		3,835		8,586
Accrued compensation and related costs		826		1,990
Accrued other		142		1,056
Total	$	7,702	$	13,901

Notes Payable

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Notes Payable

Note 8: Notes Payable

Notes payable consist of the following (in thousands):

	December 31, 2018			December 31, 2017
Notes payable under the Loan Agreement	$	14,897		$	20,000
Short-term financing		216			—
Accreted final payment (unamortized debt discount)		600			(413	)
Total notes payable		15,713			19,587
Less: Current portion		(9,383	)		(4,271	)
Total notes payable, net of current portion	$	6,330		$	15,316

In October 2016, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation and Silicon Valley Bank, under which the Company and vTv LLC borrowed $20.0 million.

Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.

The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first tranche required only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million will be due on May 1, 2020, or such earlier date specified in the Loan Agreement. The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020. In addition, a final payment for the second tranche loan equal to $0.5 million will be due on October 1, 2020, or such earlier date specified in the Loan Agreement. The availability of the third tranche of $5.0 million expired unused on June 30, 2017.

If the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance equal to 4.0% during the first 18 months following the funding of the second tranche and 2.0% thereafter.

In connection with the Loan Agreement, the Company has issued to the Lenders warrants to purchase shares of the Company’s Class A Common Stock (the “Warrants”). On October 28, 2016, the Company issued Warrants to purchase 152,580 shares of its Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0% of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the principal amount available under the second tranche of the Loan Agreement. On March 24, 2017, in connection with the funding of the second tranche, the Company issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the principal amount of the second tranche of the Loan Agreement. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets. As a result of the termination of the STEADFAST Study, the Company granted the Lenders a first priority security interest in all of the Company’s intellectual property, subject to certain limited exceptions. The Company has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.

The Loan Agreement includes customary affirmative and restrictive covenants, including, but not limited to, restrictions on the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its subsidiaries. The Loan Agreement does not contain any financial maintenance covenants other than a requirement to maintain a minimum cash balance of not less than $2.5 million in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement. The minimum cash balance covenant was included as part of an amendment to the Loan Agreement in connection with our entry into the Huadong License Agreement in December 2017. The Loan Agreement includes customary events of default, including payment defaults, covenant defaults, and material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% will be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

The Company incurred $0.7 million of costs in connection with the Loan Agreement in the year ended December 31, 2016. These costs, along with the allocated fair value of the Warrants issued of $0.9 million, were treated as a debt discount, and are offset against the carrying value of the notes payable in the Company’s Consolidated Balance Sheets as of December 31, 2018 and 2017. These costs will be recognized as interest expense over the term of the first tranche using the effective interest method. The final payment for the first and second loan tranches of $0.8 million and $0.5 million, respectively, will be accrued as additional interest expense, using the effective interest method, over the term of the relevant tranche.

The Company recorded interest expense related to the Loan Agreement of $3.1 million, $3.1 million and $0.4 million for the years ended December 31, 2018, 2017 and 2016, respectively. The annual effective interest rate on the note payable, including the amortization of the debt discounts and accretion of the final payments, is 17.7%.

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2019	$	9,383
2020		5,730
2021		—
2022		—
2023		—
Total	$	15,113

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9: Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.

Columbia University Agreement

In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments at a single digit royalty rate based on net sales of licensed products as defined in the agreement. In December 2018, the Company notified Columbia of its intent to terminate this license agreement.

Novo Nordisk

In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. Under the terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling up to $115.0 million for approval of a product. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Huadong License Agreement

Under the terms of the Huadong License Agreement, vTv LLC is responsible for sponsoring the Phase 2 MRCT including sites in both US and the Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. The Phase 2 MRCT will be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a Phase 3 clinical trial in China. vTv LLC will be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT.

Lease Agreements

The Company leases various equipment and facilities under operating leases expiring at various dates through 2019. Rent expense for non-cancelable operating leases was $0.5 million, $0.5 million and $0.6 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Future minimum lease payments under non-cancelable operating leases as of December 31, 2018 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2019	$	366
2020		—
2021		—
2022		—
2023 and thereafter		—
Total	$	366

The Company has recognized an asset retirement obligation for an obligation in its facility lease that requires the Company to return the property to the same or similar condition at the end of the lease as existed when the Company began using the facility. Asset retirement obligations recorded as a component of other noncurrent liabilities in the Consolidated Balance Sheets were $0.2 million at both December 31, 2018 and 2017. An immaterial amount of accretion and depreciation expense was recognized in the years ended December 31, 2018, 2017 and 2016.

Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Stockholders' Equity

Note 10: Stockholders’ Equity

On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A Common Stock, 100,000,000 shares of Class B Common Stock and 50,000,000 shares of preferred stock, par value $0.01 per share.

Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A Common Stock and Class B Common Stock will vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B Common Stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B Common Stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B Common Stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company.

Letter Agreement Warrants

The Company has entered into the letter agreement between vTv and M&F Group dated as of December 11, 2018 (the “December Letter Agreement”) and the letter agreements (the “Prior Letter Agreements”) with M&F Group in December 2017 and July 2018 (collectively, the “Letter Agreements”). Under the terms of the Letter Agreements, the Company has or had the right to sell to M&F Group shares of its Class A Common Stock at a specified price per share, and M&F Group has or had the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock at the same price. An aggregate of $20.0 million worth of Class A Common Stock were sold under the Prior Letter Agreements and a further $10.0 million worth of Class A Common Stock may be sold under the December Letter Agreement (whether at the Company’s or M&F Group’s option). In addition, in connection with the entrance into these Letter Agreements, the Company also issued to M&F Group warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A Common Stock. Certain terms of each of these Letter Agreements are set forth in Note 12.

The Letter Agreement Warrants were recorded as warrant liability, related party within the Company’s Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. During the years ended December 31, 2018 and 2017 the Company recognized an expense of $0.6 million and $0.2 million, respectively, related to the change in fair value of the Letter Agreement Warrants. This expense was recognized as a component of other expense, related party in the Consolidated Statements of Operations. No such expense was recognized for the year ended December 31, 2016.

Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 18 using the following assumptions:

	December 5, 2017		July 30, 2018		December 11, 2018
Expected volatility	90.0%		95.29%		104.46%
Expected life of option, in years		7.0		7.0		7.0
Risk-free interest rate	2.8%		2.94%		2.77%
Expected dividend yield	0.00%		0.00%		0.00%

Loan Agreement Warrants

On October 28, 2016, the Company entered into the Loan Agreement as discussed in Note 8. In connection with the Loan Agreement, the Company issued to the Lenders Warrants to purchase a total of 152,580 shares of the Company’s Class A Common Stock at an exercise price of $6.39 per share. Additionally, upon funding of the second tranche on March 24, 2017, the Company issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the amount available under the second tranche of the Loan Agreement. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Warrants issued with a determinable number of shares and exercise price were recorded as a component of additional paid-in capital within the Company’s Consolidated Balance Sheet as of December 31, 2016 based on their relative fair value. The Warrants issued for a variable number of shares were recorded as a component of other liabilities within the Consolidated Balance Sheet as of December 31, 2016. This related liability was adjusted to its fair value on a periodic basis until the associated warrants qualified for equity classification upon the funding of the second tranche of the Loan Agreement on March 24, 2017. For the years ended December 31, 2017 and 2016, the Company recognized additional interest expense within the Consolidated Statements of Operations of a de minimis amount related to the adjustment of the Warrants to their fair value.

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 18 using the following assumptions:

Expected volatility	82.54%
Expected life of option, in years		7.0
Risk-free interest rate	1.63%
Expected dividend yield	0.00%

Redeemable Noncontrolling Interest

12 Months Ended

Dec. 31, 2018

Noncontrolling Interest [Abstract]

Redeemable Noncontrolling Interest

Note 11: Redeemable Noncontrolling Interest

The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 53.2% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.

The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2018 and 2017, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $62.5 million and $131.4 million, respectively.

Related-Party Transactions

12 Months Ended

Dec. 31, 2018

Related-Party Transactions

Note 12: Related-Party Transactions

MacAndrews & Forbes Incorporated

MacAndrews directly or indirectly controls 23,084,267 shares of Class B Common Stock. Further, as of December 31, 2018, MacAndrews directly or indirectly holds 13,232,785 shares of the Company’s Class A Common Stock. As a result, MacAndrews’ holdings represent approximately 83.6% of the combined voting power of the Company’s outstanding common stock.

The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:

Letter Agreements

The Company has entered into the Letter Agreements with M&F Group. Under the terms of the Letter Agreements, the Company has or had the right to sell to M&F Group shares of its Class A Common Stock at a specified price per share, and M&F Group has or had the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock at the same price. An aggregate of $20.0 million worth of Class A Common Stock were sold under the Prior Letter Agreements and a further $10.0 million worth of Class A Common Stock may be sold under the December Letter Agreement (whether at the Company’s or M&F Group’s option). In addition, in connection with the entrance into these Letter Agreements, the Company also issued to M&F Group the Letter Agreement Warrants to purchase additional shares of the Company’s Class A Common Stock.

Certain terms of these Letter Agreements are set forth in the table below:

	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement
Specified purchase price per share	$	4.38	$	1.33	$	1.84
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 11, 2019
Shares available to be issued under related warrants		198,267		518,654		340,534
Exercise price of related warrants	$	5.04	$	1.53	$	2.12
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 11, 2025
Total shares issued as of December 31, 2018		2,283,105		7,518,797		815,217
Remaining shares to be issued as of December 31, 2018		—		—		4,619,566

Each of the December 5, 2017 and July 30, 2018 Letter Agreements resulted in a deemed capital contribution to the Company as the fair value of the financial instrument received by the Company exceeded the fair value of those financial instruments issued to MacAndrews. The December 11, 2018 Letter Agreement resulted in a deemed distribution to MacAndrews as the fair value of the financial instruments issued to MacAndrews exceeded the fair value of the financial instrument received by the Company. This deemed distribution has been reflected as a reduction to the net loss attributable to common shareholders of vTv Therapeutics Inc. for computing net loss per share.

Exchange Agreement

Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire Board of Directors. As of December 31, 2018, MacAndrews has not exchanged any shares under the provisions of this agreement.

Tax Receivable Agreement

The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2018.

Investor Rights Agreement

The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.

PharmaCore, Inc.

Prior to its acquisition by Cambrex Corporation in October 2016, certain controlling shareholders of the Company also controlled PharmaCore, Inc. (“PharmaCore”) and PharmaCore was therefore considered to be a related party. The Company purchased chemistry and Good Manufacturing Practices manufacturing services from PharmaCore. Total purchases from PharmaCore, while it was considered to be a related party were $0.8 million for the year ended December 31, 2016.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

Note 14: Income Taxes

From August 1, 2015, vTv Therapeutics Inc. has been subject to U.S. federal income taxes as well as state taxes. The Company recorded an income tax provision of $0.2 million and $0.8 million for the years ended December 31, 2018 and December 31, 2017, respectively, representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the year ended December 31, 2016.

As discussed in Note 12, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of December 31, 2018.

On December 22, 2017, the US government enacted comprehensive tax reform commonly referred to as the Tax Cuts and Jobs Act (“TCJA”). Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. Among other things, the TCJA (1) reduced the US statutory corporate income tax rate from 35% to 21% effective January 1, 2018, (2) eliminated the corporate alternative minimum tax, (3) eliminated the Section 199 deduction, and (4) changed rules related to uses and limitations of net operating loss carryforwards beginning after December 31, 2017.

The SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of TCJA. The purpose of SAB 118 was to address any uncertainty or diversity of view in applying ASC 740 in the reporting period in which the TCJA was enacted. Additionally, SAB 118 provided a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC 740. Based on the reduced corporate tax rate of 21%, the Company recorded a provisional decrease in its deferred tax assets of $5.8 million with a corresponding adjustment to the valuation allowance for the year ended December 31, 2017. During 2018, the Company finalized the accounting for the tax effects of TCJA with no material changes to the provisional estimate recorded.

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2018			2017			2016
U.S. statutory tax benefit	$	(4,966	)	$	(18,846	)	$	(19,374	)
Partnership income (federal) not subject to tax to the Company		3,346			13,475			13,651
Foreign withholding tax		200			800			—
State taxes (net of federal benefit)		(224	)		55			—
Impact of the Tax Act		—			5,847			—
Research and development tax credit		(1,122	)		—			—
Other		(168	)		—			—
Change in valuation allowance		3,134			(531	)		5,723
Provision for income taxes	$	200		$	800		$	—
Effective income tax rate		-0.8	%		-1.5	%		0.0	%

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforwards	$	12,749		$	9,023
Investment in partnerships		(122	)		470
Charitable contributions		11			11
Total deferred tax assets		12,638			9,504
Valuation allowance		(12,638	)		(9,504	)
Net deferred tax assets	$	—		$	—

The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as forecasts of profitability. On the basis of this evaluation, the Company concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance. During the year ended December 31, 2018, the Company’s valuation allowance increased by $3.1 million.

The Company has federal net operating loss carryforwards of $50.5 million that will be available to offset future taxable income. Approximately, $40.0 million of these carryforwards expire in varying amounts starting in 2035 to 2037, if not utilized and are available to offset 100% of future taxable income. The remaining $10.5 million may be carried forward indefinitely but are only available to offset 80% of future taxable income

The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2018, the Company had no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of December 31, 2018.

The Company files U.S. federal, Connecticut, New York, North Carolina and Virginia tax returns. The earliest open tax years that are still subject to examination by the IRS and the aforementioned state tax authorities are 2015 to 2018.

Restructuring

12 Months Ended

Dec. 31, 2018

Restructuring And Related Activities [Abstract]

Restructuring

Note 15: Restructuring

In December 2018, the Company initiated a corporate restructuring to align with a strategic decision to continue the development of its drug candidates using external resources rather than internal resources. The restructuring will allow the Company to reduce costs while continuing to conduct clinical trials, to support existing partnerships that are advancing development of additional assets, and to pursue new licensing and partnership opportunities. This restructuring included a significant reduction in its workforce. The Company expects to complete the reductions in headcount, including the payment of employee severance and benefits, in the second quarter of 2019. The Company expects these actions to result in cash charges of approximately $0.8 million for employee severance and related costs.

As of and during the year ended December 31, 2018, the Company had recognized an accrual and related expense of $0.3 million related to these severance benefits. The related expense has been recognized as a component of research and development and general and administrative expense within the Consolidated Statements of Operations based on the responsibilities of the impacted employees. The related accrual is recorded as a component of accounts payable and accrued expenses within the Consolidated Balance Sheets.

Net Loss per Share

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Net Loss per Share

Note 16: Net Loss per Share

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for the years ended December 31, 2018, 2017 and 2016 is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (amounts in thousands, except per share amounts):

	Year Ended December 31,
	2018			2017			2016
Numerator:
Net loss	$	(23,845	)	$	(54,647	)	$	(55,353	)
Less: Net loss attributable to noncontrolling interests		(15,934	)		(38,503	)		(39,001	)
Net loss attributable to vTv Therapeutics Inc.		(7,911	)		(16,144	)		(16,352	)
Less: Deemed distribution to related party (Note 12)		(739	)		—			—
Net loss attributable to common shareholders of vTv Therapeutics Inc.	$	(8,650	)	$	(16,144	)	$	(16,352	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		12,449,236			9,693,254			9,545,527
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.69	)	$	(1.67	)	$	(1.71	)

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2018		2017		2016
Class B Common Stock ⁽¹⁾		23,094,221		23,119,246		23,119,246
Common stock options granted under the Plan		1,767,503		1,960,732		1,096,101
Restricted stock units		23,333		35,000		—
Common stock options granted under the Letter Agreement		4,619,566		2,283,105		—
Common stock warrants		1,248,041		388,853		152,580
Total		30,752,664		27,786,936		24,367,927

(1)

Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Data [Abstract]

Quarterly Financial Data (Unaudited)

Note 17: Quarterly Financial Data (Unaudited)

The following interim financial information presents our 2018 and 2017 results of operations on a quarterly basis (in thousands, except per share amounts):

	2018
	March 31			June 30			September 30			December 31
Revenues	$	2,064		$	2,473		$	3,375		$	4,522
Operating loss		(9,134	)		(8,858	)		(1,481	)		(351	)
Net loss before noncontrolling interest		(9,960	)		(9,596	)		(1,961	)		(2,328	)
Net loss attributable to vTv Therapeutics Inc.		(2,952	)		(3,072	)		(796	)		(1,091	)
Net loss attributable to vTv Therapeutics Inc. common shareholders		(2,952	)		(3,072	)		(796	)		(1,830	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.30	)	$	(0.31	)	$	(0.06	)	$	(0.10	)

	2017
	March 31			June 30			September 30			December 31
Revenues	$	30		$	13		$	15		$	233
Operating loss		(13,754	)		(12,615	)		(11,541	)		(12,772	)
Net loss before noncontrolling interest		(14,286	)		(13,414	)		(12,355	)		(14,592	)
Net loss attributable to vTv Therapeutics Inc.		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss attributable to vTv Therapeutics Inc. common shareholders		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.44	)	$	(0.41	)	$	(0.38	)	$	(0.44	)

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Note 18: Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

The fair value of the Company’s Loan Agreement is considered to approximate its carrying value because it bears interest at a variable interest rate.

The Company measures the value of its investment in Reneo at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. Since acquiring the Reneo investment in December 2017, there have been no observable price changes in identical or similar investments, nor were there any indications of impairment. As such, the value of the Company’s investment in Reneo has not been remeasured.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2018, 2017 and 2016 (in thousands):

Balance at December 31, 2018

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽¹⁾

2,436

—

2,436

Total

2,436

—

2,436

Balance at December 31, 2017

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽²⁾

492

—

492

Total

492

—

492

(1)

Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.

(2)

Fair value determined using an option pricing model based on the Company’s current capitalization. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the yield of U.S. government securities with the same term as the option as of the valuation date.

	Changes in Level 3 Instruments for the years ended December 31, 2018, 2017 and 2016
	Balance at January 1		Net Change in fair value included in earnings		Purchases / Issuance		Sales / Repurchases			Balance at December 31,
2018
Warrant liability, related party	$	492	$	638	$	1,306	$	—		$	2,436
Total	$	492	$	638	$	1,306	$	—		$	2,436

2017
Warrant liability	$	167	$	—	$	—	$	(167	)	$	—
Warrant liability, related party		—		190		302		—			492
Total	$	167	$	190	$	302	$	(167	)	$	492

2016
Warrant liability	$	—	$	—	$	167	$	—		$	167
Total	$	—	$	—	$	167	$	—		$	167

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the years ended December 31, 2018, 2017 and 2016.

The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants were:

	December 31, 2018	December 31, 2017
Expected volatility	108.53% - 115.04%	90.00%
Risk-free interest rate	2.59% - 2.69%	2.40%

Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants. For the Company’s warrants, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Use of Estimates

Reclassifications

To facilitate comparison of information across periods, certain reclassifications have been made to prior period amounts to conform to the current period’s presentation.

Concentration of Credit Risk

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash and Cash Equivalents

	2018		2017
Cash and cash equivalents	$	1,683	$	11,758
Restricted cash and cash equivalents		—		162
Restricted cash and cash equivalents, long-term		2,500		2,500
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	4,183	$	14,420

Collaboration Revenue and Accounts Receivable

Property and Equipment and other Long-lived Assets

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

Investments

No adjustments have been made to the value of the Company’s investment in Reneo since its acquisition either due to impairment or based on observable price changes.

Revenue Recognition

Fair Value of Financial Instruments

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

Noncontrolling Interest

Segment and Geographic Information

Share-Based Compensation

Comprehensive Income

Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

	2018		2017
Cash and cash equivalents	$	1,683	$	11,758
Restricted cash and cash equivalents		—		162
Restricted cash and cash equivalents, long-term		2,500		2,500
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	4,183	$	14,420

Summary of Estimated Useful Lives of Property and Equipment

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Contract Liabilities Related to Company's Collaboration Agreements

Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):

	December 31, 2018		December 31, 2017
Current portion of deferred revenue	$	1,752	$	8,757
Deferred revenue, net of current portion		1,067		4,497
Total contract liabilities	$	2,819	$	13,254
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$	10,434	$	21

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Assumptions Used to Estimate Fair Value of Stock Option Awards Granted

	For the Year Ended December 31,
	2018	2017	2016
Expected volatility	71.15% - 99.23%	68.72% - 85.93%	81.57% - 87.23%
Expected life of option, in years	5.7 - 6.0	5.8 - 6.0	5.0 - 6.0
Risk-free interest rate	2.69% - 2.84%	1.87% - 2.24%	1.22% - 1.45%
Expected dividend yield	0.00%	0.00%	0.00%

Summary of Stock Award Activity for the Period

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2018 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2017		1,960,732		$	8.50
Granted		102,750			3.25
Forfeited		(295,979	)		6.27
Awards outstanding at December 31, 2018		1,767,503		$	8.57
Options exercisable at December 31, 2018		1,180,735		$	10.12
Weighted average remaining contractual term	7.1 Years
Options vested and expected to vest at December 31, 2018		1,737,666		$	8.62
Weighted average remaining contractual term	7.5 Years

Summary of Activity Related to Awards of RSUs

The following table summarizes the activity related to the awards of RSUs for the year ended December 31, 2018:

	Number of Shares			Weighted- Average Grant Date Fair Value
Awards outstanding at December 31, 2017		35,000		$	5.81
Vested		(11,667	)		5.81
Awards outstanding at December 31, 2018		23,333		$	5.81
RSUs expected to vest at December 31, 2018		23,012		$	5.81

Summary of Compensation Expense Related to Grants of Stock Options

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2018		2017		2016
Research and development	$	994	$	1,485	$	975
General and administrative		1,682		2,160		1,666
Total share-based compensation expense	$	2,676	$	3,645	$	2,641

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2018

Prepaid Expense And Other Assets Current [Abstract]

Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	December 31,
	2018		2017
Prepaid insurance	$	571	$	251
Prepaid - other		95		191
Total	$	666	$	442

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2018			2017
Laboratory equipment	$	5,690		$	6,275
Leasehold improvements		1,548			1,679
Computers and hardware		329			323
Software		691			691
Furniture and office equipment		243			431
Total property and equipment		8,501			9,399
Less: accumulated depreciation and amortization		(8,431	)		(9,116	)
Property and equipment, net	$	70		$	283

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2018		2017
Accounts payable	$	2,899	$	2,269
Accrued development costs		3,835		8,586
Accrued compensation and related costs		826		1,990
Accrued other		142		1,056
Total	$	7,702	$	13,901

Notes Payable (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following (in thousands):

	December 31, 2018			December 31, 2017
Notes payable under the Loan Agreement	$	14,897		$	20,000
Short-term financing		216			—
Accreted final payment (unamortized debt discount)		600			(413	)
Total notes payable		15,713			19,587
Less: Current portion		(9,383	)		(4,271	)
Total notes payable, net of current portion	$	6,330		$	15,316

Schedule of Principal Payments Due Under Terms of Loan Agreement

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2019	$	9,383
2020		5,730
2021		—
2022		—
2023		—
Total	$	15,113

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases

Future minimum lease payments under non-cancelable operating leases as of December 31, 2018 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2019	$	366
2020		—
2021		—
2022		—
2023 and thereafter		—
Total	$	366

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Assumptions Used to Calculate Fair Value of Warrants

Significant inputs utilized in the valuation of the Letter Agreement Warrants were:

	December 31, 2018	December 31, 2017
Expected volatility	108.53% - 115.04%	90.00%
Risk-free interest rate	2.59% - 2.69%	2.40%

Warrant Liability [Member]

Assumptions Used to Calculate Fair Value of Warrants

Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 18 using the following assumptions:

	December 5, 2017		July 30, 2018		December 11, 2018
Expected volatility	90.0%		95.29%		104.46%
Expected life of option, in years		7.0		7.0		7.0
Risk-free interest rate	2.8%		2.94%		2.77%
Expected dividend yield	0.00%		0.00%		0.00%

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 18 using the following assumptions:

Expected volatility	82.54%
Expected life of option, in years		7.0
Risk-free interest rate	1.63%
Expected dividend yield	0.00%

Related-Party Transactions (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Terms of Letter Agreements

Certain terms of these Letter Agreements are set forth in the table below:

	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement
Specified purchase price per share	$	4.38	$	1.33	$	1.84
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 11, 2019
Shares available to be issued under related warrants		198,267		518,654		340,534
Exercise price of related warrants	$	5.04	$	1.53	$	2.12
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 11, 2025
Total shares issued as of December 31, 2018		2,283,105		7,518,797		815,217
Remaining shares to be issued as of December 31, 2018		—		—		4,619,566

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2018			2017			2016
U.S. statutory tax benefit	$	(4,966	)	$	(18,846	)	$	(19,374	)
Partnership income (federal) not subject to tax to the Company		3,346			13,475			13,651
Foreign withholding tax		200			800			—
State taxes (net of federal benefit)		(224	)		55			—
Impact of the Tax Act		—			5,847			—
Research and development tax credit		(1,122	)		—			—
Other		(168	)		—			—
Change in valuation allowance		3,134			(531	)		5,723
Provision for income taxes	$	200		$	800		$	—
Effective income tax rate		-0.8	%		-1.5	%		0.0	%

Schedule of Net Deferred Tax Assets/(Liabilities)

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforwards	$	12,749		$	9,023
Investment in partnerships		(122	)		470
Charitable contributions		11			11
Total deferred tax assets		12,638			9,504
Valuation allowance		(12,638	)		(9,504	)
Net deferred tax assets	$	—		$	—

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

	Year Ended December 31,
	2018			2017			2016
Numerator:
Net loss	$	(23,845	)	$	(54,647	)	$	(55,353	)
Less: Net loss attributable to noncontrolling interests		(15,934	)		(38,503	)		(39,001	)
Net loss attributable to vTv Therapeutics Inc.		(7,911	)		(16,144	)		(16,352	)
Less: Deemed distribution to related party (Note 12)		(739	)		—			—
Net loss attributable to common shareholders of vTv Therapeutics Inc.	$	(8,650	)	$	(16,144	)	$	(16,352	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		12,449,236			9,693,254			9,545,527
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.69	)	$	(1.67	)	$	(1.71	)

Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2018		2017		2016
Class B Common Stock ⁽¹⁾		23,094,221		23,119,246		23,119,246
Common stock options granted under the Plan		1,767,503		1,960,732		1,096,101
Restricted stock units		23,333		35,000		—
Common stock options granted under the Letter Agreement		4,619,566		2,283,105		—
Common stock warrants		1,248,041		388,853		152,580
Total		30,752,664		27,786,936		24,367,927

(1)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information

The following interim financial information presents our 2018 and 2017 results of operations on a quarterly basis (in thousands, except per share amounts):

	2018
	March 31			June 30			September 30			December 31
Revenues	$	2,064		$	2,473		$	3,375		$	4,522
Operating loss		(9,134	)		(8,858	)		(1,481	)		(351	)
Net loss before noncontrolling interest		(9,960	)		(9,596	)		(1,961	)		(2,328	)
Net loss attributable to vTv Therapeutics Inc.		(2,952	)		(3,072	)		(796	)		(1,091	)
Net loss attributable to vTv Therapeutics Inc. common shareholders		(2,952	)		(3,072	)		(796	)		(1,830	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.30	)	$	(0.31	)	$	(0.06	)	$	(0.10	)

	2017
	March 31			June 30			September 30			December 31
Revenues	$	30		$	13		$	15		$	233
Operating loss		(13,754	)		(12,615	)		(11,541	)		(12,772	)
Net loss before noncontrolling interest		(14,286	)		(13,414	)		(12,355	)		(14,592	)
Net loss attributable to vTv Therapeutics Inc.		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss attributable to vTv Therapeutics Inc. common shareholders		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.44	)	$	(0.41	)	$	(0.38	)	$	(0.44	)

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements

The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2018, 2017 and 2016 (in thousands):

Balance at December 31, 2018

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽¹⁾

2,436

—

2,436

Total

2,436

—

2,436

Balance at December 31, 2017

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽²⁾

492

—

492

Total

492

—

492

(1)

(2)

	Changes in Level 3 Instruments for the years ended December 31, 2018, 2017 and 2016
	Balance at January 1		Net Change in fair value included in earnings		Purchases / Issuance		Sales / Repurchases			Balance at December 31,
2018
Warrant liability, related party	$	492	$	638	$	1,306	$	—		$	2,436
Total	$	492	$	638	$	1,306	$	—		$	2,436

2017
Warrant liability	$	167	$	—	$	—	$	(167	)	$	—
Warrant liability, related party		—		190		302		—			492
Total	$	167	$	190	$	302	$	(167	)	$	492

2016
Warrant liability	$	—	$	—	$	167	$	—		$	167
Total	$	—	$	—	$	167	$	—		$	167

Assumptions Used to Calculate Fair Value of Warrants

Significant inputs utilized in the valuation of the Letter Agreement Warrants were:

	December 31, 2018	December 31, 2017
Expected volatility	108.53% - 115.04%	90.00%
Risk-free interest rate	2.59% - 2.69%	2.40%

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jul. 29, 2015
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accumulated deficit	$ (233,883)	$ (279,058)
Cash and cash equivalents	1,683	$ 11,758
Amount remaining under letter agreement	$ 8,500
Class B Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value	$ 0.01	$ 0.01	$ 0.01
vTv Therapeutics LLC [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC	53.20%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC	46.80%
vTv Therapeutics LLC [Member] \| Class B Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value	$ 0.01

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($) Customer Segment	Dec. 31, 2017 USD ($) Customer	Dec. 31, 2016 USD ($) Customer	Jan. 01, 2018 USD ($)	Dec. 21, 2017 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable	$ 0	$ 8,000,000	$ 0
Assets held for sale	0	0
Asset impairment charges	100,000	$ 0	$ 0
Significant interest or penalties incurred related to income taxes	$ 0
Number of reportable segment \| Segment	1
ASC Topic 842 [Member]
Summary Of Significant Accounting Policies [Line Items]
Recognition of additional assets	$ 300,000
Recognition of additional liabilites	$ 300,000
Accumulated Deficit [Member] \| ASC Topic 606 [Member]
Summary Of Significant Accounting Policies [Line Items]
Net reduction in opening accumulated deficit				$ 200,000
Reneo [Member]
Summary Of Significant Accounting Policies [Line Items]
Investments, fair value					$ 2,500,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	10 years
Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	3	4	2
Revenue [Member] \| Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,683	$ 11,758
Restricted cash and cash equivalents		162
Restricted cash and cash equivalents, long-term	2,500	2,500
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$ 4,183	$ 14,420	$ 51,505	$ 88,003

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2018
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	10 years
Laboratory Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Computers and Hardware [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Computers and Hardware [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	5 years
Furniture and Office Equipment [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and Office Equipment [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	Shorter of useful life or remaining term of lease

Collaboration Agreements - Additional Information (Detail) - USD ($)			1 Months Ended		12 Months Ended
	Dec. 21, 2017	Mar. 06, 2015	May 31, 2018	Aug. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized					$ 10,434,000	$ 21,000
Research and development					23,035,000	39,640,000	$ 44,953,000
Collaborative Arrangements [Member] \| Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum contribution amount to clinical trial					3,000,000
Collaborative Arrangements [Member] \| Reneo [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received	$ 3,000,000
Unrecognized amount of transaction price allocated to performance obligation					1,700,000
Collaboration revenue recognized					3,700,000	100,000	0
Collaborative Arrangements [Member] \| Reneo [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential development and regulatory milestone payments	94,500,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received	8,000,000
Potential regulatory milestone payments based on regulatory approval	20,000,000
Potential sales-based milestones based on tiered sales of licensed products	50,000,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized amount of transaction price allocated to performance obligation					1,000,000
Maximum contribution amount to clinical trial	3,000,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Phase 2 MRCT [Member] \| License and Technology Transfer Services of Chemistry and Manufacturing Know-How [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized					6,800,000	100,000	0
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Obligation to Sponsor and Conduct Portion of Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized					0
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Obligation to Sponsor and Conduct Portion of Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized						0	0
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Joint Development Committee [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized amount of transaction price allocated to performance obligation					100,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential development and regulatory milestone payments	$ 25,000,000
Collaborative Arrangements [Member] \| Newsoara Biopharma Co., Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received			$ 2,000,000
Potential development and regulatory milestone payments			$ 63,000,000
Collaboration revenue recognized					2,000,000	$ 0	$ 0
Collaborative Arrangements [Member] \| JDRF [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum research funding receivable achievement based on research and development milestones				$ 3,000,000
Maximum funding percentage of research and development milestones				50.00%
Funding received					800,000
Research and development					$ 800,000
Collaborative Arrangements [Member] \| Calithera [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received		$ 600,000
Collaboration revenue recognized		$ 300,000
License agreement termination date					Dec. 21, 2017

Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Current portion of deferred revenue	$ 1,752	$ 8,757
Deferred revenue, net of current portion	1,067	4,497
Total contract liabilities	2,819	13,254
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$ 10,434	$ 21

Share-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period	3 years	3 years
Non-qualified stock option awards expiration term	10 years	10 years
Compensation expense related to share-based awards	$ 2,676,000	$ 3,645,000	$ 2,641,000
Tax benefit related to stock option awards	0	$ 0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 1,300,000
Weighted average period to recognize unrecognized share-based compensation cost	1 year 3 months 18 days
Weighted average grant date fair value of options granted	$ 2.28	$ 4.15	$ 4.05
Aggregate intrinsic value of outstanding awards	$ 100,000
Aggregate intrinsic value of outstanding awards unvested	$ 100,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period to recognize unrecognized share-based compensation cost	1 year 2 months 12 days
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 100,000
2015 Omnibus Equity Incentive Plan [Member] \| Class A Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded	3,250,000

Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	71.15%	68.72%	81.57%
Expected life of option, in years	5 years 8 months 12 days	5 years 9 months 18 days	5 years
Risk-free interest rate	2.69%	1.87%	1.22%
Maximum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	99.23%	85.93%	87.23%
Expected life of option, in years	6 years	6 years	6 years
Risk-free interest rate	2.84%	2.24%	1.45%

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share Based Arrangements To Obtain Goods And Services [Abstract]
Number of Shares, Awards outstanding, Beginning balance \| shares	1,960,732
Number of Shares, Granted \| shares	102,750
Number of Shares, Forfeited \| shares	(295,979)
Number of Shares, Awards outstanding, Ending balance \| shares	1,767,503
Number of Shares, Options exercisable \| shares	1,180,735
Number of Shares, Options exercisable, Weighted average remaining contractual term	7 years 1 month 6 days
Number of Shares, Options vested and expected to vest \| shares	1,737,666
Number of Shares, Options vested and expected to vest, Weighted average remaining contractual term	7 years 6 months
Weighted-Average Exercise Price, Awards outstanding, Beginning balance \| $ / shares	$ 8.50
Weighted-Average Exercise Price, Granted \| $ / shares	3.25
Weighted-Average Exercise Price, Forfeited \| $ / shares	6.27
Weighted-Average Exercise Price, Awards outstanding, Ending balance \| $ / shares	8.57
Weighted-Average Exercise Price, Options exercisable \| $ / shares	10.12
Weighted-Average Exercise Price, Options vested and expected to vest \| $ / shares	$ 8.62

Share-Based Compensation - Summary of Activity Related to Awards of RSUs (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Awards outstanding, Beginning balance \| shares	35,000
Number of Shares, Vested \| shares	(11,667)
Number of Shares, Awards outstanding, Ending balance \| shares	23,333
Number of Shares, RSUs expected to vest \| shares	23,012
Weighted-Average Grant Date Fair Value, Awards outstanding, Beginning balance \| $ / shares	$ 5.81
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	5.81
Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance \| $ / shares	5.81
Weighted-Average Grant Date Fair Value, RSUs expected to vest \| $ / shares	$ 5.81

Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,676	$ 3,645	$ 2,641
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	994	1,485	975
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 1,682	$ 2,160	$ 1,666

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expense And Other Assets Current [Abstract]
Prepaid insurance	$ 571	$ 251
Prepaid - other	95	191
Total	$ 666	$ 442

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Total property and equipment	$ 8,501	$ 9,399
Less: accumulated depreciation and amortization	(8,431)	(9,116)
Property and equipment, net	70	283
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	5,690	6,275
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	1,548	1,679
Computers and Hardware [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	329	323
Software [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	691	691
Furniture and Office Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 243	$ 431

Accounts Payable and Accrued Expenses - Accounts payable and accrued expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Accounts payable	$ 2,899	$ 2,269
Accrued development costs	3,835	8,586
Accrued compensation and related costs	826	1,990
Accrued other	142	1,056
Total	$ 7,702	$ 13,901

Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes payable under the Loan Agreement	$ 14,897	$ 20,000
Short-term financing	216
Accreted final payment (unamortized debt discount)	(600)	413
Total notes payable	15,713	19,587
Less: Current portion	(9,383)	(4,271)
Total notes payable, net of current portion	$ 6,330	$ 15,316

Notes Payable - Additional Information (Detail) - USD ($)			1 Months Ended		12 Months Ended
	Mar. 24, 2017	Oct. 28, 2016	Mar. 31, 2017	Oct. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Loan borrowed amount					$ 500,000	$ 7,500,000	$ 12,500,000
Costs incurred in connection with loan agreement							673,000
Allocated fair value of warrants issued							923,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate on note payable					17.70%
Loan and Security Agreement [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate floor				0.50%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Loan borrowed amount				$ 20,000,000
Debt instrument, interest rate floor				10.50%
Variable rate basis					one-month LIBOR
Interest rate description					Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.
Warrant exercise price condition					Exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants.
Warrants expiration period		7 years
Minimum cash balance required in deposit account				$ 2,500,000
Additional default interest rate				5.00%
Costs incurred in connection with loan agreement							700,000
Allocated fair value of warrants issued							900,000
Interest expense related to loan agreement					$ 3,100,000	$ 3,100,000	$ 400,000
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments for First 18 Months [Member]
Debt Instrument [Line Items]
Prepayment penalty fee				4.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments Thereafter [Member]
Debt Instrument [Line Items]
Prepayment penalty fee				2.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche One [Member]
Debt Instrument [Line Items]
Loan borrowed amount				$ 12,500,000
Debt instrument, payment terms					The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first tranche required only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020.
Debt instrument, final payment				$ 800,000
Debt instrument, maturity date				May 01, 2020
Debt instrument, frequency of periodic Payment					monthly
Warrants to purchase shares of common stock		152,580
Exercise price of warrants		$ 6.39
Warrant shares percentage issued of loan amount		6.00%
Final payment, accrued additional interest expense					$ 800,000
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two [Member]
Debt Instrument [Line Items]
Loan borrowed amount			$ 7,500,000
Debt instrument, payment terms					The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020.
Debt instrument, final payment				$ 500,000
Debt instrument, maturity date				Oct. 01, 2020
Debt instrument, frequency of periodic Payment					monthly
Warrants to purchase shares of common stock	38,006
Exercise price of warrants	$ 5.92
Warrant shares percentage issued of loan amount	3.00%	3.00%
Final payment, accrued additional interest expense					$ 500,000
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Three [Member]
Debt Instrument [Line Items]
Loan amount available for borrowing					$ 5,000,000
Tranches expiration date					Jun. 30, 2017

Notes Payable - Schedule of Principal Payments Due Under Terms of Loan Agreement (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Debt Disclosure [Abstract]
2019	$ 9,383
2020	5,730
Total	$ 15,113

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Feb. 28, 2007
Commitments And Contingencies [Line Items]
Lease termination description		operating leases expiring at various dates through 2019
Asset retirement obligations, noncurrent			$ 200,000
Non-cancelable Operating Leases [Member]
Commitments And Contingencies [Line Items]
Rent expense for operating leases		$ 500,000	$ 500,000	$ 600,000
Developmental and Regulatory Milestone Payment [Member] \| Novo License Agreement [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment					$ 115,000,000
Sales-based Milestones Payment [Member] \| Novo License Agreement [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment					$ 75,000,000
Phase 2 MRCT [Member] \| Collaborative Arrangements [Member]
Commitments And Contingencies [Line Items]
Maximum contribution amount to clinical trial		$ 3,000,000
Columbia University [Member]
Commitments And Contingencies [Line Items]
Annual fee obligated to pay under the agreement	$ 100,000
Annual fee payment obligation period		2015 through 2021
Columbia University [Member] \| Regulatory Milestone Payment [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 800,000

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2019	$ 366
Total	$ 366

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions			12 Months Ended
	Mar. 24, 2017 $ / shares shares	Oct. 28, 2016 $ / shares shares	Dec. 31, 2018 USD ($) Vote $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 05, 2017 USD ($)	Jul. 29, 2015 $ / shares shares
Class Of Stock [Line Items]
Preferred stock, shares authorized \| shares						50,000,000
Preferred stock par value \| $ / shares						$ 0.01
Common stock, voting rights			Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
Aggregate amount of common stock may be sold \| $			$ 8.5
Change in fair value of consideration warrants expense \| $			$ 0.6	$ 0.2
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member]
Class Of Stock [Line Items]
Warrant exercise price condition			Exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants.
Warrants expiration period		7 years
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche One [Member]
Class Of Stock [Line Items]
Warrants to purchase shares of common stock \| shares		152,580
Exercise price of warrants \| $ / shares		$ 6.39
Warrant shares percentage issued of loan amount		6.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two [Member]
Class Of Stock [Line Items]
Warrants to purchase shares of common stock \| shares	38,006
Exercise price of warrants \| $ / shares	$ 5.92
Warrant shares percentage issued of loan amount	3.00%	3.00%
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares			100,000,000	100,000,000		100,000,000
Common stock par value \| $ / shares			$ 0.01	$ 0.01		$ 0.01
Common stock, vote per share \| Vote			1
Class A Common Stock [Member] \| M&F Group [Member]
Class Of Stock [Line Items]
Aggregate amount of common stock may be sold \| $					$ 20.0
Class A Common Stock [Member] \| December Letter Agreement [Member] \| M&F Group [Member]
Class Of Stock [Line Items]
Aggregate amount of common stock may be sold \| $					$ 10.0
Class B Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares			100,000,000	100,000,000		100,000,000
Common stock par value \| $ / shares			$ 0.01	$ 0.01		$ 0.01
Common stock, vote per share \| Vote			1

Stockholders' Equity - Assumptions Used to Calculate Fair Value of Warrants (Detail)	Dec. 31, 2018 yr	Dec. 11, 2018 yr	Jul. 30, 2018 yr	Dec. 05, 2017 yr
Letter Agreement Warrants [Member] \| Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input		104.46	95.29	90.0
Letter Agreement Warrants [Member] \| Expected Life of Option, in Years [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input		7.0	7.0	7.0
Letter Agreement Warrants [Member] \| Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input		2.77	2.94	2.8
Letter Agreement Warrants [Member] \| Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input		0.00	0.00	0.00
Loan Agreement Warrants [Member] \| Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	82.54
Loan Agreement Warrants [Member] \| Expected Life of Option, in Years [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	7.0
Loan Agreement Warrants [Member] \| Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	1.63
Loan Agreement Warrants [Member] \| Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.00

Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Noncontrolling Interest [Line Items]
Redemption amount of noncontrolling interest	$ 62.5	$ 131.4
Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Number of days used to determine exchange value based on weighted average price of Class A common stock	20 days
Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Stock conversion ratio	1.00
vTv Therapeutics LLC [Member]
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage	53.20%

Related-Party Transactions - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($) shares	Dec. 31, 2016 USD ($)
Related Party Transaction [Line Items]
Aggregate amount of common stock may be sold	$ 8,500,000
Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Related Party Transaction [Line Items]
Stock conversion ratio	1.00
MacAndrews & Forbes Incorporated [Member]
Related Party Transaction [Line Items]
Ownership percentage of majority owner	83.60%
Amount of cash savings percentage	85.00%
Description of tax receivable agreement	The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
MacAndrews & Forbes Incorporated [Member] \| Class B Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party \| shares	23,084,267
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party \| shares	13,232,785
Aggregate amount of common stock may be sold	$ 20,000,000
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Related Party Transaction [Line Items]
Stock conversion ratio	1.00
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member] \| December Letter Agreement [Member]
Related Party Transaction [Line Items]
Aggregate amount of common stock may be sold	$ 10,000,000
PharmaCore, Inc. [Member]
Related Party Transaction [Line Items]
Total purchases from related party		$ 800,000

Related-Party Transactions - Summary of Terms of Letter Agreements (Detail) - MacAndrews & Forbes Incorporated [Member] - Class A Common Stock [Member] - $ / shares	Dec. 11, 2018	Jul. 30, 2018	Dec. 05, 2017
2017 Letter Agreement [Member]
Class Of Warrant Or Right [Line Items]
Specified purchase price per share			$ 4.38
Expiration date of letter agreement			Dec. 05, 2018
Shares available to be issued under related warrants			198,267
Exercise price of related warrants			$ 5.04
Expiration date of related warrants			Dec. 05, 2024
Total shares issued as of December 31, 2018			2,283,105
2018 Letter Agreement [Member]
Class Of Warrant Or Right [Line Items]
Specified purchase price per share	$ 1.84	$ 1.33
Expiration date of letter agreement	Dec. 11, 2019	Jul. 30, 2019
Shares available to be issued under related warrants	340,534	518,654
Exercise price of related warrants	$ 2.12	$ 1.53
Expiration date of related warrants	Dec. 11, 2025	Jul. 30, 2025
Total shares issued as of December 31, 2018	815,217	7,518,797
Remaining shares to be issued as of December 31, 2018	4,619,566

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Income tax provision	$ 200,000	$ 800,000	$ 0
US statutory corporate income tax rate	21.00%	35.00%
Provisional decrease in deferred tax assets		$ 5,847,000
Increase in valuation allowance	$ 3,100,000
Uncertain tax positions	0
Increase decrease in uncertain tax position reasonably possible	0
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 50,500,000
Net operating loss carryforwards, limitations on use	Approximately, $40.0 million of these carryforwards expire in varying amounts starting in 2035 to 2037, if not utilized and are available to offset 100% of future taxable income. The remaining $10.5 million may be carried forward indefinitely but are only available to offset 80% of future taxable income
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Earliest open tax year	2015 2016 2017 2018
Minimum [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2035
Maximum [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2037
Expire in 2035 to 2037 [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 40,000,000
Maximum percentage of taxable income limited to offset by net operating loss carryforwads.	100.00%
Indefinite [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 10,500,000
Maximum percentage of taxable income limited to offset by net operating loss carryforwads.	80.00%
M&F TTP Holdings LLC [Member]
Income Taxes [Line Items]
Amount of cash savings percentage	85.00%

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S. statutory tax benefit	$ (4,966,000)	$ (18,846,000)	$ (19,374,000)
Partnership income (federal) not subject to tax to the Company	3,346,000	13,475,000	13,651,000
Foreign withholding tax	200,000	800,000
State taxes (net of federal benefit)	(224,000)	55,000
Impact of the Tax Act		5,847,000
Research and development tax credit	(1,122,000,000)
Other	(168,000,000)
Change in valuation allowance	3,134,000	(531,000)	5,723,000
Provision for income taxes	$ 200,000	$ 800,000	$ 0
Effective income tax rate	(0.80%)	(1.50%)	0.00%

Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 12,749	$ 9,023
Investment in partnerships assets		470
Investment in partnerships liabilities	(122)
Charitable contributions	11	11
Total deferred tax assets	12,638	9,504
Valuation allowance	$ (12,638)	$ (9,504)

Restructuring - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2019	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Restructuring, initiation date			Dec. 11, 2018
Accrual and related expense related to severance benefits	$ 0.3		$ 0.3
Scenario Forecast [Member]
Restructuring Cost And Reserve [Line Items]
Employee severance and related costs		$ 0.8

Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net loss	$ (2,328)	$ (1,961)	$ (9,596)	$ (9,960)	$ (14,592)	$ (12,355)	$ (13,414)	$ (14,286)	$ (23,845)	$ (54,647)	$ (55,353)
Less: Net loss attributable to noncontrolling interests									(15,934)	(38,503)	(39,001)
Net loss attributable to vTv Therapeutics Inc.	(1,091)	(796)	(3,072)	(2,952)	(4,311)	(3,650)	(3,963)	(4,220)	(7,911)	(16,144)	(16,352)
Less: Deemed distribution to related party (Note 12)									(739)
Net loss attributable to common shareholders of vTv Therapeutics Inc.	$ (1,830)	$ (796)	$ (3,072)	$ (2,952)	$ (4,311)	$ (3,650)	$ (3,963)	$ (4,220)	$ (8,650)	$ (16,144)	$ (16,352)
Class A Common Stock [Member]
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted									12,449,236	9,693,254	9,545,527
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.10)	$ (0.06)	$ (0.31)	$ (0.30)	$ (0.44)	$ (0.38)	$ (0.41)	$ (0.44)	$ (0.69)	$ (1.67)	$ (1.71)

Net Loss per Share - Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	30,752,664	27,786,936	24,367,927
Class B Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	23,094,221	23,119,246	23,119,246
Common Stock Options Granted Under the Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	1,767,503	1,960,732	1,096,101
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	23,333	35,000
Common Stock Options Granted Under the Letter Agreement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	4,619,566	2,283,105
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	1,248,041	388,853	152,580

Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Data [Line Items]
Revenues	$ 4,522	$ 3,375	$ 2,473	$ 2,064	$ 233	$ 15	$ 13	$ 30	$ 12,434	$ 291	$ 634
Operating loss	(351)	(1,481)	(8,858)	(9,134)	(12,772)	(11,541)	(12,615)	(13,754)	(19,824)	(50,682)	(55,020)
Net loss before noncontrolling interest	(2,328)	(1,961)	(9,596)	(9,960)	(14,592)	(12,355)	(13,414)	(14,286)	(23,845)	(54,647)	(55,353)
Net loss	(1,091)	(796)	(3,072)	(2,952)	(4,311)	(3,650)	(3,963)	(4,220)	(7,911)	(16,144)	(16,352)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (1,830)	$ (796)	$ (3,072)	$ (2,952)	$ (4,311)	$ (3,650)	$ (3,963)	$ (4,220)	$ (8,650)	$ (16,144)	$ (16,352)
Class A Common Stock [Member]
Quarterly Financial Data [Line Items]
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.10)	$ (0.06)	$ (0.31)	$ (0.30)	$ (0.44)	$ (0.38)	$ (0.41)	$ (0.44)	$ (0.69)	$ (1.67)	$ (1.71)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

Fair Value of Financial Instruments - Summary of Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	$ 492	$ 167
Net Change in fair value included in earnings	638	190
Purchases / Issuance	1,306	302	$ 167
Sales / Repurchases		(167)
Balance at December 31,	2,436	492	167
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	492
Net Change in fair value included in earnings	638	190
Purchases / Issuance	1,306	302
Balance at December 31,	2,436	492
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1		167
Purchases / Issuance			167
Sales / Repurchases		(167)
Balance at December 31,			$ 167
Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	2,436	492
Fair Value, Measurements, Recurring [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	2,436	492
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	2,436	492
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	$ 2,436	$ 492

Fair Value of Financial Instruments - Summary of Significant Inputs Utilized in the Valuation of 2017 and 2018 Agreement Warrants (Detail) - 2017 and 2018 Agreement Warrants [Member]	Dec. 31, 2018	Dec. 31, 2017
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants		0.9000
Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants		0.0240
Minimum [Member] \| Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.0853
Minimum [Member] \| Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0259
Maximum [Member] \| Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.1504
Maximum [Member] \| Risk-Free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0269

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - Class A Common Stock [Member] - MacAndrews & Forbes Incorporated [Member] - December Letter Agreement [Member] $ / shares in Units, $ in Millions	Jan. 01, 2019 USD ($) $ / shares shares
Subsequent Event [Line Items]
Warrants to purchase shares of common stock \| shares	2,445,651
Exercise price of warrants \| $ / shares	$ 1.84
Funding received \| $	$ 4.5

Collaboration Agreements - Additional Information (Detail 1)	Dec. 31, 2018
Collaborative Arrangements [Member] \| Reneo [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remainder of performance obligation expected recognition period	5 months 15 days